Using a mathematical model abstracted from the complex network in Figure S1 , we illustrate the biochemical mechanisms and conditions under which these signaling molecules operate. A system of ordinary differential equations was utilized to understand the intracellular dynamics. In order to incorporate the signaling network we simplified the network as shown in Figure S1A as follows: We merged all the regulatory network between proteasome/Bcl2 and NFκB -Bcl2 into one component (NFκB-Bcl2 complex; middle green box with dashed line in Figure S1A ) while we kept IκB (dashed yellow box in Figure S1A ) and Bax (dashed blue box in Figure S1A ) in separate modules. The corresponding mathematical model network is shown in Figure S1B . We refer to the interactions represented by edges in Figure S1B as the core control system. By convention, the kinetic interpretation of arrows and hammerheads in the chemical network signify induction (arrow) and inhibition (hammerhead).
where the first term in Eq. (1) represents the signaling pathways from bortezomib to IκB in the absence and presence of OVs, k SB is the signaling strength of bortezomib, B is the bortezomib level, k 12 is a scaling factor for inhibition of the bortezomib signaling, k 13 is the inhibition strength of bortezomib signaling by OVs, [oHSV] is a biochemical switch for oncolytic viruses with [oHSV] = v k+v where v is the OV density, as introduced below, and k is the Hill type parameter, giving [oHSV] = 0 (1) in the absence (presence) of virus, c 1 , c 2 , k 10 are the signaling pathways to the proteasome-NFκB -Bcl-2 complex, Bax, and RIP1, respectively, k 1 , k 2 , k 3 are the autocatalytic enhancement parameters for IκB, proteasome-NFκB-Bcl-2 complex and Bax, respectively, k 2 , k 4 , k 8 are the Hill-type inhibition saturation parameters from the counter part of IκB, proteasome-NFκB -Bcl-2 complex and Bax, respectively, k 5 is the inhibition strength of IκB by the proteasome-NFκB-Bcl-2 complex, k 6 is the inhibition strength of the proteasome-NFκB-Bcl-2 complex by IκB, k 9 is the inhibition strength of the Bax by the , and finally, µ s , µ f , µ a , µ r are decay rates of IκB, proteasome-NFκB-Bcl-2 complex, Bax, RIP1, respectively.
By performing the following non-dimensionalization:
of Eqs. (1)- (4), we obtain the dimensionless equations for IκB (S), NFκB-Bcl2 (F ), Bax (Ā), RIP1 (R) with a set of essential control parameters:
where [oHSV] =v k+v wherev is the dimensionless OV density, as introduced below. Table S1 . Reference value used in the model.
Diffusible variables (x, y, n, v, B)
The following nondimensionalization was used for the governing equations (8)- (12) in the main text
to get the dimensionless model equations:
*Note that β † = β, β † 3 = β 3 , δ † = δ under the assumption of x * = y * = n * ; otherwise β † , β † 3 , δ † are different from β, β 3 , δ, respectively. Table S1 lists the reference values in the model.
Boundary Condition:
We take no-flux boundary condition for all diffusible variables (x, y, v, B) on the boundary Γ = ∂Ω
where ν is the outer normal vector.
2 Parameter estimation ω 1 , ω 2 , ω 3 : Half-life of suppressor (IκB) is in the range of (10-40) mins [14] [15] [16] . By taking 40 mins of half-life, we get µ s = ln(2)/(40 min) = 1.0 h −1 . We take 2.2 hours of half-life for the NFκB-Bcl2 complex, leading to µ f = 0.315 h −1 and ω 1 = µ f µs = 0.3. Half-life of Bax is approximated to be in the range of (6-32) hours [17] , leading to µ a = ln (2) 
. Random motility of infected cells is very limited due to OV infection and we take much slower value,
We assume that effect of OV replication doubles when B = B * , (i.e., , 1 + α 1 B * = 2), based on experimental observation [2] . So, we take α 1 = 10 11 mm 3 /g.
We take the bortezomib level (B * ) to indicate the instant consumption of bortezomib by tumor cells, leading to k B = B * = 1.0 × 10 −11 g/mm 3 .
µ B : The average half-life of Bortezomib was estimated to be 10-31 hours [20] . The mean removal halflife of after the first dose was in the range of 9-15 hours at the dose level 1.45-2.00 mg/m 2 in cancer patients [21] . We take 20 h, leading to µ B = 
